Practical aspects of new oral anticoagulant use in atrial fibrillation

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 3, 2014, Pages 124-135

  Undas, Anetta ^a,b   Pasierski, Tomasz ^c   Windyga, Jerzy ^d   Crowther, Mark ^e  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^c Miedzyleski Central Hospital   (Poland)

^d INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

Apixaban; Atrial fibrillation; Dabigatran; Rivaroxaban; Stroke

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; MULTIDRUG RESISTANCE PROTEIN; RIVAROXABAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMORBIDITY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY FUNCTION; MECHANICAL HEART VALVE; MEDICAL RECORD REVIEW; MITRAL VALVE REGURGITATION; PATIENT SELECTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERSONAL EXPERIENCE; PROTEIN BINDING; REIMBURSEMENT; REVIEW; RISK FACTOR; SEVERE RENAL IMPAIRMENT; TRANSIENT ISCHEMIC ATTACK; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; ORAL DRUG ADMINISTRATION; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; STROKE; THIOPHENES; WARFARIN;

EID: 84907684888     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2138     Document Type: Review

References (39)

1. Riva N, Lip G Y. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long-term prevention of thromboembolic complications in patients with atrial fibrillation? Pol Arch Med Wewn. 2012;122:45-53.
2. Cairns JA. Prevention of stroke and systemic embolization in atrial fibrillation: a Canadian perspective. Pol Arch Med Wewn. 2012;122:428-436.
3. Kornej J, Potpara T, Lip GY. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. Pol Arch Med Wewn. 2013;123:623-634.
4. Connolly SJI, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrilation. N Engl J Med. 2009;361:1139-1151.
5. Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
6. Granger CB, Alexander JH, McMurray JJV, et al.; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
7. Camm AJ, Lip GY, Atar D, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
8. Nataios G. Papavasileiou V, Diener HD, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack. A systematic review and meta-analysis of randomized controlled trials. Stroke. 2012;43:3298-3304.
9. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5:480-486.
10. Lip G Y, Larsen TB, Skjøth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012;60:738-746.
11. Dalen JE. Should the newer oral anticoagulants be withheld from patients with valvular AF? Chest. 2013;144:369-370.
12. Eikelboom JW, Connolly SJ, Brueckmann M, et al.; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369:1206-1214.
13. Stöllberger C, Finsterer J. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging. 2013;30:949-958.
14. Poli D, Antonucci E, Testa S, et al.; Italian Federation of Anticoagulation Clinics. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation. 2011;124:824-829.
15. Maccallum PK, Mathur R, Hull SA, et al. Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. BMJ Open. 2013;3:e003 343.
16. Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625-651.
17. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016-3023.
18. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.
19. Liew A, Darvish-Kazem S, Douketis JD. Is there a role for novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials. Pol Arch Med Wewn. 2013;123:617-622.
20. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11:245-252.
21. Tripodi A. The laboratory and the new oral anticoagulants. Clin Chem. 2013;59:353-362.
22. Baglin T. The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost. 2013;11(Suppl 1):122-128.
23. Baglin T, Hillarp A, Tripodi A, et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013. doi: 10.1111/jth.12 149. Epub ahead of print.
24. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
25. Liew A, Douketis J. Perioperative management of patients who are receiving a novel oral anticoagulant. Intern Emerg Med. 2013;8:477-484.
26. Gallego P, Apostalakis S, Lip G Y. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation. 2012;126:1573-1576.
27. Wysokinski WE, McBane RD 2nd. Periprocedural bridging management of anticoagulation. Circulation. 2012;126:486-490.
28. Ferrandis R, Castillo J, De Andrés J, et al. The perioperative management of new direct oral anticoagulants: a question without answers. Thromb Haemost. 2013;110:515-522.
29. Sié P, Samama CM, Godier A, et al.; Working Group on Perioperative Haemostasis; French Study Group on Thrombosis and Haemostasis. Surgery and invasive prodecures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis. 2011;104:669-676.
30. Huisman MV, Lip G Y, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thomb Haemost. 2012;107:838-847.
31. McGrath ER, Eikelboom JW, Kapral MK, O'Donnell MJ. Novel oral anticoagulants: a focused review for stroke physicians. Int J Stroke. 2014;9:71-78.
32. Shibazaki K, Kimura K, Aoki J, et al. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci. 2013;331:90-93.
33. Guo Y, Lip G Y, Apostolakis S. Bleeding risk assessment and management in atrial fibrillation patients. Key messages for clinical practice from the European Heart Rhythm Association position statement. Pol Arch Med Wewn. 2012;122:235-242.
34. Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost. 2014;111:14-18.
35. Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61:2264-2273.
36. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325-2332.
37. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J. 2013;34:489-498b.
38. Siegal DM, Garcia DA, Crowther MA. How I treat: target specific oral anticoagulant associated bleeding. Blood. 2014;123:1152-1158.
39. Douketis JD. Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management. Pol Arch Med Wewn. 2011;121:73-80.